Apexigen Stock

apexigen.comHealthcare / BioTech & PharmaFounded: 2010Funding to Date: $165.38MM

Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMAB™, the Company’s proprietary antibody drug discovery platform.

Register To Buy and Sell Shares

For more details on financing and valuation for Apexigen, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Apexigen’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Apexigen.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Amy Wong
Vice President, Finance
Ovid Trifan MD
Chief Medical Officer
Xiaodong Yang Ph.D
Chief Executive Officer, President and Board Member
Mark Nevins
Vice President of Business Development
Frances Rena Bahjat Ph.D
Vice President of Discovery Research

Board Members

Herb Cross
William Rutter Ph.D
Dan Zabrowski Ph.D
Decheng Capital
George Lee Ph.D
Amkey Ventures
Xiaodong Yang Ph.D
Karen Liu Ph.D
3E Bioventures Capital
Kenneth Fong Ph.D
Kenson Ventures
Updated on: Feb 28, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.